Treatments for Mesothelioma Under Investigation

Researchers continually find ways to treat diseases that seem counter-intuitive to the rest of us. There are hundreds of clinical trials underway at any given time. Clinical trials are research programs that are approved for trial on humans. These trials are restricted to people who meet inclusion and exclusion criteria for that specific study. Clinical trials conducted through four trial phases, each involving a larger number of participants. The fourth phase is a post marketing study.

Several clinical trials are using gene therapy to stimulate immune responses in humans. One treatment in Phase I involves injecting a dose of a gene therapy involving a virus thymidine kinase into the intrapleural space (between the two pleural mesothelial membranes that line the lungs and ribcage) twice daily for 3 days. This treatment showed sufficient promise in the treatment of pleural mesothelioma to recommend it for Phase II testing. Several other gene therapy trials by different groups of researchers use variations of gene therapy with promising results. These trials involved patients with localized pleural mesothelioma.

A double-blind study in Phase II Trial will compare the results of administering the combination of Gemcitabine and Cisplatin with, and without Bevacizumab, a drug that inhibits the growth of blood vessels that can nourish new cancer cells in the hope that the tumor will shrink.

Pemetrexed combined with Cisplatin was compared to Cisplatin alone in a Phase III trial involving patients with metastatic pleural mesothelioma (MPM). The combination of both drugs with the addition of vitamin B12 and folic acid “resulted in superior survival time, time to progression, and response rates…” Adding the vitamins reduced toxicity.

Another study in Phase I involves Pemetrexed and Carboplatin in patients with MPM. During Phase I some of the patients experienced toxicity related to the dosage, however, 70% of the patients experienced improvement in their symptoms after only two courses of treatment. Time to progression was delayed 305 days (about ten months) and median survival time 451 days (about fifteen months.)

Photodynamic therapy is another approach that is currently being studied. Patients are pretreated with light-sensitive molecules that cause the cancer cells to become sensitive to light. During surgery, these cells are exposed to light of a specific wavelength. Though there have been positive results, this treatment also requires more study.

In comparison, the patients who qualified for these clinical trials had a life expectancy of six to nine months at the time they entered the trials. While there is still a long way to go, scientists are working to find the key to curing mesothelioma. In the past surgery was done as a palliative treatment.

Fifteen years ago researchers were hopeful that surgery combined with chemotherapy, radiation therapy would provide more significant results than each give separately. Today, therapy combining surgery with chemotherapy, photodynamic therapy and gene therapy are producing encouraging results.

You may be entitled to compensation if you have received a diagnosis of mesothelioma or asbestosis. Please visit the website of Parker, Dumler & Kiely, LLP, the experienced mesothelioma lawyers in Baltimore, Maryland and Washington, D.C.